Stoke Therapeutics Inc
STOK
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.83B
Close$
$-2.95
111.6% downside
Current Fair Value
111.6% downsideOvervalued by 111.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.83 Billion |
|---|---|
| Enterprise Value | $1.74 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.12 |
| Beta | 1.23 |
| Outstanding Shares | 66,017,894 |
Return
| Return on Equity | -60.17% |
|---|---|
| Return on Assets | -52.77% |
| Return on Invested Capital | -63.45% |
Valuation & Multiples
| P/E Ratio | -8.46 |
|---|---|
| PEG | -5.21 |
| Price to Sales | - |
| Price to Book Ratio | 5.06 |
| Enterprise Value to Revenue | 62.91 |
| Enterprise Value to EBIT | -7.77 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$4.89 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.88
Average shareholder expectationRevenue Estimate
$8.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.3778▼ 107.62% |
|---|---|
| Total Calls | 22,500▼ 79.28% |
| Total Puts | 31,000▼ 88.37% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 116.21%▲ 3.43% |
|---|---|
| Total Invested | $2.51B▲ 8.42% |
| Investors Holding | 203▼ 3.00% |
ESG Score
No data
About Stoke Therapeutics Inc
CEO: Edward Kaye